U.S. Stem Cell, Inc. (USRM)

OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
At close: Feb 26, 2026
0.00%
Market Cap 66.15K
Revenue (ttm) 82.05K
Net Income (ttm) -2.86M
Shares Out 661.51M
EPS (ttm) -0.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,240
Average Volume 459,845
Open 0.0001
Previous Close 0.0001
Day's Range 0.0001 - 0.0001
52-Week Range 0.0000 - 0.0002
Beta -115.46
RSI 54.37
Earnings Date Apr 14, 2026

About U.S. Stem Cell

U.S. Stem Cell, Inc. engages in the research, development, and commercialization of stem cell and regenerative treatments in the United States and internationally. The company develops MyoCell, an autologous muscle stem cell therapy which is preparing for phase II/III clinical trials for the treatment of heart damage in heart failure patients; MyoCell SDF-1, an autologous cell therapy which completed the IND application for the treatment of chronic damage in the heart and enhancement of blood vessel formation; and AdipoCell, a clinical protocol... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 11
Stock Exchange OTCMKTS
Ticker Symbol USRM
Full Company Profile

Financial Performance

In 2022, U.S. Stem Cell's revenue was $82,049, a decrease of -59.13% compared to the previous year's $200,749. Losses were -$2.86 million, -13.06% less than in 2021.

Financial Statements

News

There is no news available yet.